3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
4
Neoplasm Metastasis
3
Neoplasms by Site
2
Neoplasms
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Oxaliplatin
21
pembrolizumab
17
Capecitabine
15
Nivolumab
13
Paclitaxel
12
Fluorouracil
12
Leucovorin
11
Docetaxel
10
atezolizumab
7
Trastuzumab
7
tislelizumab
5
Ramucirumab
5
durvalumab
4
Standard of Care
4
Magnetic Resonance Spectroscopy
4
Irinotecan
4
Cisplatin
4
Carboplatin
4
zolbetuximab
3
zimberelimab
3
apatinib
3
Specimen Handling
3
S 1 (combination)
3
Gemcitabine
3
Bevacizumab
3
trifluridine tipiracil drug combination
2
tremelimumab
2
trastuzumab deruxtecan
2
relatlimab
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Stomach Neoplasms
×
AZD9833
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled